Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt: 2010-2021

Historic Short term Debt for Anika Therapeutics (ANIK) over the last 5 years, with Dec 2021 value amounting to $4.3 million.

  • Anika Therapeutics' Short term Debt fell 74.42% to $4.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was $4.3 million, marking a year-over-year decrease of 74.42%. This contributed to the annual value of $4.3 million for FY2021, which is 67.04% down from last year.
  • According to the latest figures from FY2021, Anika Therapeutics' Short term Debt is $4.3 million, which was down 67.04% from $13.1 million recorded in FY2020.
  • Over the past 5 years, Anika Therapeutics' Short term Debt peaked at $13.1 million during FY2020, and registered a low of $4.3 million during FY2021.
  • In the last 2 years, Anika Therapeutics' Short term Debt had a median value of $8.7 million in 2020 and averaged $8.7 million.
  • Data for Anika Therapeutics' Short term Debt shows a maximum YoY tumbled of 67.04% (in 2021) over the last 5 years.
  • Over the past 2 years, Anika Therapeutics' Short term Debt (Yearly) stood at $13.1 million in 2020, then slumped by 67.04% to $4.3 million in 2021.